drugset / Trial / NCT02859142

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

NCT02859142

Phase 4 Completed 122 enrolled University of Chicago Pfizer · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to learn if the combination of a study drug and patch is more effective in helping heavy drinkers stop smoking than just the patch alone The study drug, varenicline, has been approved by the Food and Drug Administration (FDA) to help people stop smoking, but it is not known if the addition of varenicline to standard smoking cessation treatment with nicotine patches will help people stop smoking who are regular, frequent drinkers. This study is being done because cigarette smoking is the number one preventable cause of death and disease in the United States.

Timeline

Start
2018-03-29
Primary completion
2020-09-30
Completion
2020-10-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 1 mg
Background Nicotine Unknown 7 mg Other